CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

Fernando MorenoVega IranzoI. ÁlvarezAntonio AntónJosé Ignacio ChacónJoaquín GaviláMichael S. MartinPedro Sánchez‐RoviraPaula GratalM J Fernández González2026-03-222026-03-22202510.1007/s12094-025-03896-zhttps://doi.org/10.1007/s12094-025-03896-zhttps://andeanlibrary.org/handle/123456789/53629Citaciones: 1enMedicineFulvestrantBreast cancerOncologyEndocrine systemInternal medicineDiseaseClinical PracticeAromataseCancerCDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptionsarticle